2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
COVID-19
6
Neoplasms
2
Hematologic Neoplasms
2
Severe Acute Respiratory Syndrome
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Mastocytosis
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hypersensitivity
1
Hematopoietic and Lymphatic System Neoplasm
1
Chronic Disease
1
Interventions
Cytarabine
561
Azacitidine
385
venetoclax
311
Cyclophosphamide
289
fludarabine
246
fludarabine phosphate
229
Decitabine
187
Busulfan
176
Daunorubicin
155
Idarubicin
151
Peripheral Blood Stem Cell Transplantation
138
Mycophenolic Acid
134
Filgrastim
134
Whole-Body Irradiation
133
Tacrolimus
125
Granulocyte Colony-Stimulating Factor
124
Etoposide
117
Mitoxantrone
103
Methotrexate
103
Melphalan
103
Cyclosporine
101
Antilymphocyte Serum
85
Gemtuzumab
84
Clofarabine
84
Specimen Handling
73
Injections
69
Stem Cell Transplantation
64
Biopsy
57
CPX-351
56
Thiotepa
54
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Acute
×
BNT162 Vaccine
×
Clear all
NCT04969601
2024-06-26
PACIFIC
Assistance Publique - Hôpitaux de Paris
Phase 1/2
Completed
76 enrolled